About WaferGen
WaferGen is a company based in Fremont (United States) founded in 2002 was acquired by Takara Bio in May 2016. WaferGen offers products and services including Biotech Kits, Reagents, and Instruments. WaferGen operates in a competitive market with competitors including Arbor Biotechnologies, Singleron, Octant, Diagenode and Factor Bioscience, among others.
- Headquarter Fremont, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Takara Bio Usa, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$510 K (USD), Post-IPO
Aug 22, 2014
-
Investors
Takara Bio
& 4 more
-
Employee Count
Not available
-
Acquired by
Takara Bio
(May 13, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of WaferGen
WaferGen offers a comprehensive portfolio of products and services, including Biotech Kits, Reagents, and Instruments.
Kits for gene discovery and nucleic acid purification
Reagents for PCR and gene editing processes
Instruments for single-cell sequencing and analysis
Funding Insights of WaferGen
Investors in WaferGen
WaferGen has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Takara Bio, Oxford Finance and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for WaferGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by WaferGen
Investment portfolio details for WaferGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - WaferGen
Detailed financials for WaferGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Wafergen Comparisons
Peer comparison for WaferGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of WaferGen
WaferGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arbor Biotechnologies, Singleron, Octant, Diagenode and Factor Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| Locked | Locked | Locked |
Human cell interaction platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Reagents and kits for epigenetics sequencing solutions are developed.
|
|
| Locked | Locked | Locked |
Genomic technologies are developed to treat diseases and enhance health.
|
|
| Locked | Locked | Locked |
Creates innovative in-vitro diagnostic technologies for cancer detection.
|
Detailed competitors of WaferGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Wafergen
Complete news archive for WaferGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about WaferGen
WaferGen was founded in 2002 and raised its 1st funding round 5 years after it was founded.
WaferGen is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
WaferGen offers a set of tools for molecular and single-cell analysis in the life sciences, pharmaceutical, and clinical laboratory industries. Its products include ICELL8 Single-Cell System (for single-cell research); NGS Library Prep system, SmartChip NGS Target Enrichment System and Real-Time PCR System. It also provides chips, printed panels, primers and reagent kits for Single Cell Analysis, NGS Sample Prep, and Clinical Research.
WaferGen's top competitors include Arbor Biotechnologies, Singleron and Diagenode.
WaferGen offers Biotech Kits, Reagents, and Instruments.
WaferGen has 5 investors. Key investors include Takara Bio, Oxford Finance, Great Point Partners, Deerfield, and Merlin Nexus.